🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

RecruitingNAAges 30 Years - 74 YearsFemaleUniversity of California, San Francisco
NCT02620852 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Most physicians still use a one-size-fits-all approach to breast screening in which all women, regardless of their personal history, family history or genetics (except BReast CAncer gene (BRCA) carriers) are recommended to have annual mammograms starting at age 40. Mammograms benefit women by detecting cancers early when they are easier to treat, but they are not perfect. Recent news stories have discussed some of the potential harms: large numbers of positive results that cause stressful recalls for additional mammograms and biopsies. With the current screening approach, half of the women who undergo annual screening for ten years will have at least one false positive biopsy. Potentially more important are cancer diagnoses for growths that might never come to clinical attention if left alone (called "overdiagnosis"). This can lead to unnecessary treatment. Even more concerning is eviden

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Female\* 2. Age 30 years to 74 years old\*\* 3. Reside in the United States\*\*\* NOTE\*: As of 2019, we are now enrolling all persons who identify as female, and will capture both their sex at birth and gender identity in the baseline survey. NOTE\*\*: Eligibility from 2016 - October 2023 included ages 40-74 (WISDOM 1.0) and expanded to age 30 in October 2023 (WISDOM 2.0). NOTE\*\*\*: As of 2019, recruitment is available nationwide. Original eligibility was limited to California, North Dakota, South Dakota, Iowa, Minnesota, Alabama, Louisiana, Illinois OR have coverage from a participating health plan. Exclusion Criteria: 1. Prior Breast cancer or ductal carcinoma in situ (DCIS) diagnosis 2. Prior prophylactic bilateral mastectomy 3. Inability to provide consent 4. Non-English or Spanish proficiency (Spanish participation available: June 2019)
💊

What it tests

  • Complete a health questionnaire
  • Provide a saliva sample for genetic testing
  • Screening advice based on a comprehensive risk assessment
  • Screening advice based on a basic risk assessment
📍

Where

11 sites
University of Alabama at Birmingham
Birmingham, United States
University of California Irvine
Irvine, United States
University of California Los Angeles
Los Angeles, United States
University of California Davis
Sacramento, United States
University of California San Diego
San Diego, United States
University of California San Francisco
San Francisco, United States
TopLine MD Alliance
Miami, United States
University of Chicago
Chicago, United States

…and 3 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy